anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a medicament for treating gastropathy, and particularly relates to a Chinese patent medicinal preparation for treating various kinds of gastritis. The invention aims to a medicament for treating gastropathy. The medicament has the special effect on the gastropathy such as gastric ulcer, atrophic gastritis, superficial gastritis, hypertrophic gastritis, chronic gastritis and the like. The Chinese medicinal ingredients are high in action and safety; the lethal dose (LD40) of oral administration is more than 5 g/kg, the medicament does not have a mutagenic effect; and according to study on the pharmacologic effect of the medicament deeply, a medicinal effect is confirmed, active substances are definite basically, and the quality is controllable. After medicine withdrawal, the relapse rate is low, and the side effect is less by the oral administration. In the technical scheme, the Chinese patent medicinal preparation for treating various kinds of gastritis comprises the following Chinese raw material compositions: south nutgrass galingale rhizome, trogopterus dung, morning glory seed and Shanxi millet vinegar, wherein the Chinese medicine prepared from the raw materials are an effective dose applied in medical science. The Chinese patent medicinal preparation is high in effectiveness, pharmacological activity and safety and low in production cost, has a new mechanism of action and a curative effect, addresses symptoms and root causes and eliminates pathogens and strengthens the body resistance and does not have toxicity, and common patients can afford the medicament; and patients who suffer from the gastropathy account for about 30 percent of ordinary people, so the Chinese patent medicinal preparation can create good social benefit.
Capecitabine tablets USP are fluoropyrimidine carbamate with antineoplastic activity. It is an orally administered systemic prodrug of 5'-deoxy-5-fluorouridine (5'-DFUR) which is converted to 5- fluorouracil.

The chemical name for Capecitabine, USP is 5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine and has a molecular weight of 359.35. Capecitabine has the following structural formula:

Capecitabine, USP is a white to off-white crystalline powder with an aqueous solubility of 26 mg/mL at 20ºC.

Capecitabine tablets USP are supplied as capsule shaped, biconvex film coated tablets for oral administration. Each light pink-colored tablet contains 150 mg capecitabine and each dark pink-colored tablet contains 500 mg capecitabine. The inactive ingredients in Capecitabine tablets USP include: anhydrous lactose, croscarmellose sodium, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium stearate and purified water. The light or dark pink film coating contains hydroxypropyl methylcellulose, talc, titanium dioxide, yellow iron oxide, and red iron oxide.
The invention relates to a lipid lowering nutrition powder made from chick peas and a preparation method thereof. The nutrition powder takes chick peas, onion juice or an onion aqueous extract and a fruit flavor as raw materials, and the lipid lowering nutrition powder is refined by the unique process according to the nutritional requirements and the traditional dietary habits of Uygur minority. The lipid lowering nutrition powder is rich in natural vegetable protein, 18 amino acids, crude fat, crude dietary fiber, polysaccharide, a plurality of vitamins and a plurality of mineral substances, and nutrients such as linoleic acid, linoleic acid etc.; the nutrition powder contains prostaglandin A (the special nutrient components of onion), physiological activators (diallyl disulfide), sulfur amino acid, etc. The lipid lowering nutrition powder made from chick peas strengthens the efficacies of chick peas in reducing blood lipid, blood pressure and blood sugar, and is beneficial to strengthening human immunity. The natural lipid lowering nutrition powder with high nutrition is necessary for patients with hyperlipoidemia, hypertension, diabetes, and children, the middle-aged and the elderly.
The present invention relates to a medicine and food dual purpose traditional Chinese medicine for preventing and treating parasites in alimentary canals, and a preparation method thereof. The traditional Chinese medicine is prepared from medicinal materials officially used as a medicine and food: sophora flower, dark plum fruit, Pericarpium Zanthoxyli, grand torreya seed, parslane herb and star anise as traditional Chinese medicine raw materials. The medicine adopts different medications to expel parasites; for example, firstly, the acidity of the dark plum fruit is utilized to tranquilize the parasites, the Pericarpium Zanthoxyli is used for releasing or weakening the absorbing function of the parasite's osculum, and thus, the parasites are easy to expel without pain, etc. Moreover, the medicine has no toxic or side effect and can be mainly used for preventing ascariasis for a long time. The present invention has the advantages of low production cost, no environmental pollution, wide adaptability for all people in different ages, good taste, low dosage and obvious effect, and can be easily accepted by patients. Furthermore, because all medicinal materials officially used as both medicine and food have obvious effect and no toxic or side effect, the medicine has wide service range suitable for all the people, simple and clear medicine varieties and functions without dispute, flexible and multiple prescriptions, suitability for various illness conditions, pertinent medication selection, wider specific content and wider application range of the traditional Chinese medicine on distinguishing and treating different symptoms.
<P>PROBLEM TO BE SOLVED: To obtain a compact powder type cosmetic composition having a solid fat phase.  <P>SOLUTION: This cosmetic composition is the compact powder type cosmetic composition used for making up and/or caring the skin, especially face and contains a powdery phase and a fat phase containing at least one solid fat phase, wherein, the solid fat phase presents in such an amount that the compact powder has a stickiness corresponding to <12 wt. % mass loss evaluated by a falling down testing, and the powdery phase has stickiness producing a compactness corresponding to ≥12 wt. % mass loss evaluated by the falling down testing and/or a compactness without being eroded uniformly in the case of being used at a ratio of 91.2 wt. % as a mixture with 8.8 wt. % reference liquid binder as described in a working example 1 and also in the case that the whole part is compacted by 2x10<SP>7</SP>Pa pressure.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The active comparator meditation group will complete a 10-week meditation yoga intervention (2x/week, 45 minutes per session). Each session will consist of yogic breathing, imagery, and meditation, specifically with a focus on each of the yogic limbs. The yogic limbs that will be incorporated during the meditation intervention are yamas, niyamas, pranayamas, and sense withdrawal/meditative techniques.
The invention discloses preparation and application of recombinant plectasin. The method comprises designing plectasin gene according to preferred codons of Pichia pastoris, wherein possible nucleotide sequences of the plectasin gene are expressed in SEQ ID NO. 1, constructing recombinant expression vectors pPICPlectasin and recombinant genetic engineering bacteria Pichia pastoris X33pPICPlectasin (CGMCC NO. 3564), carrying out a high density fermentation process on the recombinant genetic engineering bacteria Pichia pastoris having a high expression level, wherein a total protein concentration of supernate from the high density fermentation process is 729 microgrammes per milliliter, dialyzing and freeze-drying the supernate, and orderly carrying out a gel filtration chromatography treatment and a reversed phase high performance liquid chromatogram treatment on the freeze-dried supernate to obtain high purity recombinant plectasin. The high purity recombinant plectasin is not hemolytic, has favorable PH stability, heat stability and anti-pepsin activity, and can inhibit effectively the growth of gram-positive pathogen Streptococcus pneumonia, staphylococcus aureus and staphylococcus epidermidis. Therefore, the high purity recombinant plectasin can be utilized for treating and preventing gram-positive bacterium and especially streptococcus and has potential antimicrobial drug development values.
Since December 2019, patients with unexplained pneumonia have appeared in some medical institutions in Wuhan, China. Nucleic acid testing was completed on January 10, 2020, which was confirmed to be caused by 2019-novel coronavirus. In 2020, the World Health Organization(WHO) named the virus 2019-novel coronavirus(2019-nCoV). The WHO announced that the pneumonia caused by 2019-nCoV is officially called COVID-19. Today, more than 70,000 cases have been confirmed and more than 2,000 patients have died.

At present, the epidemiological characteristics, laboratory indicators, imaging features and clinical treatment effects of COVID-19 should be reported, but the sample size is small. Large sample studies are still needed to further confirm COVID-19 's disease progression, clinical characteristics, disease severity and treatment effects, so as to provide a scientific basis for future clinical treatment. Therefore, it is particularly important to further review the relationship between the characteristics and prognosis of such patients.
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only potentially curative therapy for patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, relapse remains a leading cause for treatment failure after hematopoietic cell transplantation (HCT) in patients, optimization of conditioning regimen can improve prognosis and decrease relapse. Abnormal gene methylation is common in AML and MDS patients. Azacytidine is a DNA methylation transferase inhibitor that can re-express tumor suppressor genes in leukemia cells. Venetoclax is a selective BCL-2 inhibitor, which has antitumor activity against a variety of hematological malignancies. The combination of the two drugs show a synergistic anti-tumor effect. The objective of this study is to evaluate the safety and efficacy of VEN-AZA regimen followed by Allo-HSCT in the treatment of high-risk MDS and high-risk or relapsed/refractory AML.
The present invention discloses a preparation method of a blood embolism material of injected isopropyl acrylamide terpolymer and application thereof. The present invention belongs to the preparative technique of the blood vessel embolism material in the bio-medical engineering field. Mono-propyl acrylamide is generated by the reaction of propenoyl chloride and n-propylamine, and subsequently is synthesized into a polymer PNINAVP in a water solvent by ammonium persulphate as an initiating agent and tetramethylethylenediamine as an accelerating agent. Iohexol is dissolved in a polymer solution to obtain an iohexol polymer solution which can form the embolism of an abnormal net in a pig brain so that the technology can be applied to the embolism treatment of the arteriovenous malformation of the human brain. The present invention has the advantage that an LCST of the terpolymer approaches to the body temperature so that the rapid transformation from collosol to gel can be realized rapidly. The polymer and the iohexol are combined together in the process of the transformation from the collosol to the gel in the iohexol polymer solution, which is good for the material development in vivo and the iohexol toxicity reduction. The added iohexol can enhance the gel strength so that the mistake embolism of the material in vivo can be avoided.
NOCDURNA can cause hyponatremia [see Boxed Warning and Adverse Reactions (6.1)]. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated, leading to seizures, coma, respiratory arrest, or death.

NOCDURNA is contraindicated in patients at increased risk of severe hyponatremia, such as those with excessive fluid intake, those who have illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids [see Contraindications (4), and Drug Interactions (7.1)].

Prior to starting or resuming NOCDURNA, ensure that the serum sodium concentration is normal.

Limit fluid intake to a minimum from 1 hour before administration until 8 hours after administration. Use of NOCDURNA without concomitant reduction of fluid intake may lead to fluid retention and hyponatremia. Advise patients to avoid drinks containing caffeine or alcohol before bedtime. Monitor the serum sodium concentration within 1 week and approximately 1 month of initiating NOCDURNA, and periodically thereafter. The frequency of serum sodium monitoring should be based on the patient's risk for hyponatremia. The incidence of hyponatremia was higher in patients 65 years of age or older compared to younger patients. More frequent monitoring is recommended for patients 65 years of age or older or those on concomitant medications that can increase the risk of hyponatremia, such as tricyclic antidepressants, selective serotonin reuptake inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), chlorpromazine, opiate analgesics, carbamazepine, lamotrigine, thiazide diuretics and chlorpropamide [see Drug Interactions (7.1)].

If hyponatremia occurs, NOCDURNA may need to be temporarily or permanently discontinued and treatment for the hyponatremia instituted, depending on the clinical circumstances, including the duration and severity of the hyponatremia.

Women are more sensitive to the effects of NOCDURNA compared to men [see Clinical Pharmacology (12.2)]. The recommended dose for women is lower than for men because women had a higher risk of hyponatremia with the 55.3 mcg dose in clinical trials.
An isolated stage one oocyte from sturgeon. The stage one germ cell is isolated from stage II ovaries and incubated with trypsin and collagenase and either PBS, Hank’s balanced salt solution or Leibovitz medium. The suspension was then filtered and centrifuged to obtain early previtellogenic oocytes. The primary stage previtellogenic oocytes may be used in a cosmetic composition, nutritional composition or a nutraceutical composition. The early previtellogenic oocytes may be produced by the induction of differentiation of primordial germ cells. Also disclosed are immortalised sturgeon primordial germ cells, and immortalised sturgeon germ cells, such as stage 1 oocytes, stage 2 oocytes, stage 3 oocytes, stage 4 oocytes, stage 5 oocytes, and spermatozoa. Extracts, cosmetics, nutritional products and nutraceutical products are disclosed comprising any of these cell types. Also disclosed is production of sturgeon sperm by the induction of differentiation of primordial germ cells.
ARDS is a serious condition that involves inflammation and fluid accumulation in the lungs, leading to low blood oxygen levels and breathing failure. It is often fatal and affects approximately 150,000 individuals each year in the United States. Common underlying causes include bacterial infections, lung trauma, and pneumonia. Even in people with similar risk factors for ARDS, there are often varying levels of condition severity. This may be because some people experience an ongoing viral infection that further predisposes them to the bacterial infection, worsening the severity of ARDS. Viruses release a protein called Type I interferon. This protein increases the response of the interferon stimulated genes (ISG) in neutrophils, which are white blood cells that protect the body against disease and infections by destroying bacteria. Preliminary studies have shown that some people at risk for ARDS have elevated ISGs in their neutrophils and that ISGs are associated with an impaired neutrophil response and increased severity of ARDS. This study will evaluate the association between viral-related neutrophil ISG response and the severity of ARDS.

Participants will include people on mechanical ventilation who are enrolled in either the ARDSNet 06 or 07 studies. For this study, participants will undergo blood collection within 48 hours of beginning the main ARDSNet study. There will be no study visits specifically for this study. Study researchers will analyze participants' blood samples and ARDSNet study data to gather information on mortality, the number of ventilator-free days, markers of severity of organ dysfunction and inflammation, and neutrophil response.
Each participant completed a dedicated session for mock scanning before we acquired two sets of sMRI and fMRI scans. One scan set was collected using the head mold and the other without, and the scans were counterbalanced in order across participants. Using a specialized sMRI sequence embedded with vNAVs, we directly measured head motion during sMRI in order to more accurately evaluate the head mold's impact on structural metrics. To evaluate the feasibility and tolerability of the head mold, we concluded the scanning sessions with a brief interview that gauged participants' scanning experience and tolerance of the head mold. We investigated whether head molds would reduce head motion compared to standard scanning procedures and whether those reductions would result in improved data quality. We also tested the extent to which reductions in head motion impacted estimations of cortical volume and functional connectivity. Prior to data collection, we evaluated the noise dosage levels of the head mold condition, given the limited space available for additional hearing protection devices in the head coil while the head mold is on. We also assessed whether the head molds could balance head motion between typical and ADHD populations, and whether clinical variables such as ADHD diagnosis and trait anxiety, as determined by parent-reported dimensional measures, can predict head mold efficacy.
Sotalol hydrochloride can cause serious and potentially fatal ventricular arrhythmias such as sustained VT/VF, primarily Torsade de Pointes (TdP) type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. Factors such as reduced creatinine clearance, female sex, higher doses, reduced heart rate and history of sustained VT/VF or heart failure increase the risk of TdP. The risk of TdP can be reduced by adjustment of the sotalol dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval [see Dosage and Administration (2.1)].

Correct hypokalemia or hypomagnesemia prior to initiating sotalol hydrochloride, as these conditions can exaggerate the degree of QT prolongation, and increase the potential for Torsade de Pointes. Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs.

Proarrhythmic events must be anticipated not only on initiating therapy, but with every upward dose adjustment [see Dosage and Administration (2.1)].

In general, do not use sotalol with other drugs known to cause QT prolongation [see Drug Interactions (7.1)].
PURPOSE: Although infundibular dilatations (IDs) have been thought to be benign anatomical variants, case reports suggest that they can grow and rupture. The aim of this study was to determine whether IDs have a tendency to grow or rupture.
METHODS: The study population was collected from the Tampere University Hospital (TAUH) Aneurysm Database. The presence of IDs was screened from the medical records and imaging studies of 356 intracranial aneurysm patients left to follow-up from 2005 to 2020. The imaging studies were reviewed to confirm the IDs, and their clinical course. Finally, we performed a systematic review of published cases of ID leading to aneurysmatic rupture from PubMed.
RESULTS: We found 97 typical IDs in 83 patients and 9 preaneurysmal lesions resembling ID in 9 patients. Out of the typical cone-shaped IDs, none grew or ruptured in a total follow-up of 409 patient-years. One preaneurysmal lesion ruptured during a follow-up: this lesion had components of both infundibular dilatation and aneurysm at the beginning of follow-up. In the systematic literature search, we found 20 cases of aneurysmatic SAHs originating from an ID. Of those, only 7 had imaging available prerupture. All 7 IDs were typically cone-shaped, but a branching vessel originating from the apex of ID was only seen in 4/7.
CONCLUSION: Typical infundibular dilatations seem to be benign anatomical variants that are stable and, thus, do not need prophylactic treatment or imaging follow-up. Likely, the SAHs reported from IDs were actually caused by misdiagnosed preaneurysmal lesions.
Patients will be treated with 250ml of normal saline 0.9% or 5% dextrose water as single intravenous infusion of one hour within 72 hours from the start of standard-of-care treatment. Standard-of-care treatment will be prescribed to all patients at the discretion of the attending physicians according to local guidelines or to their own decision.
PURPOSE: The surgical approach to bowel endometriosis is still unclear. The aim of the study is to compare TICA to conventional specimen extractions and extra-abdominal insertion of the anvil in terms of both complications and functional outcomes.
METHODS: This is a single-center, observational, retrospective study conducted enrolling symptomatic women underwent laparoscopic excision of deep endometriosis with segmental bowel resection between September 2019 and June 2022. Women who underwent TICA were compared to classical technique (CT) in terms of intra- and postoperative complications, moreover, functional outcomes relating to the pelvic organs were assessed using validated questionnaires [Knowles-Eccersley-Scott-Symptom (KESS) questionnaire and Gastro-Intestinal Quality of Life Index (GIQLI)] for bowel function. Pain symptoms were assessed using Visual Analogue Scale (VAS) scores.
RESULTS: The sample included 64 women. TICA was performed on 31.2% (n = 20) of the women, whereas CT was used on 68.8% (n = 44). None of the patients experienced rectovaginal, vesicovaginal, ureteral or vesical fistula, or ureteral stenosis and uroperitoneum, and in no cases was it necessary to reoperate. Regarding the two surgical approaches, no significant difference was observed in terms of complications. As concerns pain symptoms at 6-month follow-up evaluations on stratified data, except for dysuria, all VAS scales reported showed significant reductions between median values, for both surgery interventions. As well, significant improvements were further observed in KESS scores and overall GIQLI. Only the GIQLI evaluation was significantly smaller in the TICA group compared to CT after the 6-month follow-up.
CONCLUSIONS: We did not find any significant differences in terms of intra- or post-operative complications compared TICA and CT, but only a slight improvement in the Gastro-Intestinal Quality of Life Index in patients who underwent the CT compared to the TICA technique.
The present invention belongs to the field of biomedicine technology, and discloses one kind of tumor apoptosis inducing ligandin and its application in preparing antitumor medicine. The present invention discloses two kinds of tumor apoptosis inducing ligand gene oligonucleotide sequences, as shown separately in SEQ ID No. 1 and SEQ ID No. 2. The present invention also discloses the tumor apoptosis inducing ligandin Trail the above-mentioned expresses and its use in preparing tumor cell treating medicine. The present invention is significant in developing tumor treating medicine.